Branched-chain amino acids in liver diseases

Kazuto Tajiri, Yukihiro Shimizu

Kazuto Tajiri, The Third Department of Internal Medicine, Toyama University Hospital, Toyama 930-0194, Japan
Yukihiro Shimizu, Gastroenterology Unit, Nanto Municipal Hospital, Toyama 932-0211, Japan

Author contributions: Tajiri K wrote the second half of the manuscript; and Shimizu Y wrote the first half of the manuscript and organized the whole manuscript.

Correspondence to: Yukihiro Shimizu, MD, PhD, Gastroenterology Unit, Nanto Municipal Hospital, Nanto, Toyama 932-0211, Japan. rsf14240@nifty.com

Received: June 24, 2013
Revised: August 12, 2013
Accepted: September 15, 2013
Published online: November 21, 2013

Abstract

Branched chain amino acids (BCAAs) have been shown to affect gene expression, protein metabolism, apoptosis and regeneration of hepatocytes, and insulin resistance. They have also been shown to inhibit the proliferation of liver cancer cells in vitro, and are essential for lymphocyte proliferation and dendritic cell maturation. In patients with advanced chronic liver disease, BCAA concentrations are low, whereas the concentrations of aromatic amino acids such as phenylalanine and tyrosine are high, conditions that may be closely associated with hepatic encephalopathy and the prognosis of these patients. Based on these basic observations, patients with advanced chronic liver disease have been treated clinically with BCAA-rich medicines, with positive effects.

INTRODUCTION

The three branched chain amino acids (BCAAs), leucine, isoleucine and valine, are among the nine essential amino acids for humans. Recent studies have revealed the functions of these BCAAs, and they have been administered for the treatment of advanced liver diseases. In this review, we summarize current understanding of the biological properties of BCAAs and review the results of clinical application of BCAAs to treat patients with liver diseases.

BASIC ASPECTS OF BCAAS IN LIVER

Serum concentration of BCAAs in patients with chronic liver diseases and liver cirrhosis

Serum concentrations of BCAAs are decreased, while the concentrations of the aromatic amino acids (AAAs) phenylalanine and tyrosine are increased, in patients with advanced liver diseases, resulting in a low ratio of BCAAs to AAAs, a ratio called the Fischer ratio[1]. A low Fischer ratio has been associated with hepatic encephalopathy (HE). The imbalance of amino acids tends to become more marked with the progression of liver diseases, and aminograms are useful for assessing the prognosis of cir-
rhotic patients with or without hepatocellular carcinoma (HCC)\cite{30}. Moreover, a simplified Fischer ratio, the BCAA to tyrosine ratio (BTR), has been reported useful for predicting serum albumin concentration one year later\cite{20}. These data indicate that amino acid imbalance, either low Fischer ratio or BTR, is a marker for progression of liver diseases, and that correcting this ratio may have therapeutic potential, not only for nutritional improvement, but also for HE, in patients with advanced liver diseases.

**Gene expression and mitochondrial biogenesis**

In mice, BCAA-rich diets have shown to up-regulate the expression of peroxisome proliferator-activated receptor (PPAR) \(\gamma\) coactivator-1\(\alpha\) (PGC-1\(\alpha\)), a master regulator of mitochondrial biogenesis and the defense system against reactive oxygen species (ROS), and of sirtuin-1, a member of the sirtuin family linked to life span extension, enhanced mitochondrial biogenesis, and decreased ROS production, leading to the prolongation of the lifespan of male mice\cite{19}. BCAAs have also been shown to induce the activation of genes involved in antioxidant defenses and inhibition of ROS production, as well as to induce the hepatic expression of mRNA encoding 8-oxoguanine DNA glycosylase 1, an enzyme involved in repair of oxidative DNA damage, in a rat model of liver injury, indicating that BCAAs are involved in the induction of antioxidant DNA repair\cite{29}.

In various cell lines, BCAAs, especially leucine, have been shown to activate the mammalian target of rapamycin (mTOR) signals, stimulating the synthesis of proteins, including albumin, and of glycogen\cite{27}. The ability of leucine to enhance glucose metabolism was confirmed in normal rats and in a rat cirrhosis model. BCAA activation of mTORC1 has also been associated with cell growth\cite{9} and PGC-1\(\alpha\)-mediated mitochondrial gene expression\cite{21}. BCAAs have been shown to up-regulate PPAR-\(\gamma\) and uncoupling protein (UCP) 2, reducing triglyceride concentrations in mouse livers\cite{19}. These findings suggest that BCAAs may have a therapeutic effect on metabolic disorders and/or obesity.

**Apoptosis and regeneration of hepatocytes**

BCAA supplementation was shown to delay the progression of CCI\(_4\)-induced chronic liver injury in a rat model by reducing hepatic apoptosis\cite{11}. On the other hand, BCAAs promoted hepatocyte regeneration in a rat model of hepatocarcinoma\cite{22}. Moreover, BCAAs were reported to stimulate the production of hepatocyte growth factor\cite{23}. Taken together, these findings indicate that supplementation with BCAAs, by reducing hepatocyte apoptosis and promoting liver regeneration, may result in rapid recovery from liver injury.

**Albumin synthesis**

BCAAs activate mTOR and subsequently increase the production of eukaryotic initiation factor 4E-binding protein-1 and ribosomal protein S6 kinase, which upregulate the synthesis of albumin\cite{24-26}. Furthermore, leucine stimulates the nuclear importation of polypyrimidinetract-binding protein, which binds to albumin mRNA and increases its translation\cite{27}.

**Insulin resistance**

BCAAs were shown to improve homeostasis model assessment scores for insulin resistance (HOMA-IR) and beta cell function (HOMA-\%B) in patients with chronic liver disease, indicating that BCAAs can ameliorate insulin resistance\cite{31}. In mice lacking the gene encoding mitochondrial BCAA aminotransferase, an enzyme that catalyzes BCAAs, serum BCAA concentrations were elevated. In those mice, fasting blood glucose and insulin concentrations were decreased and HOMA-IR was significantly lower than in wild-type mice\cite{6}. Furthermore, administration of leucine or isoleucine improved insulin sensitivity in mice with high-fat diets\cite{23,24,25}. BCAAs were also shown to temporarily increase plasma insulin concentrations in healthy young men, although plasma glucose concentrations were not altered\cite{15}.

Several organs are involved in the mechanism by which BCAAs improve insulin resistance. In the liver, BCAAs increase the liver X receptor/sterol regulatory element binding protein-1c pathway and subsequently activate liver-type glucokinase and glucose transporter. Furthermore, BCAAs suppress hepatic expression of glucose-6-phosphatase\cite{21}. In adipose tissue, leucine increases insulin-induced phosphorylation of Akt and mTOR, increasing glucose uptake\cite{27}. In skeletal muscle, BCAAs promote glucose uptake through activation of phosphatidylinositol 3-kinase (PI3K) and protein kinase C and subsequent translocation of glucose transporter to the plasma membrane\cite{28}. In addition, BCAAs increase PPAR-\(\gamma\) and subsequent UCP2 in liver and UCP3 in muscle, stimulating oxidation of free fatty acids. Thus, BCAAs improve insulin resistance through interactions in organs targeted by insulin.

**Liver cancer cells**

The direct effects of BCAAs on liver cancer cells have been analyzed in culture systems. Increased concentrations of BCAAs in culture medium were reported to suppress the proliferation of HCC cell lines\cite{26}. Moreover, all three BCAAs were found to accelerate insulin-induced vascular endothelial growth factor (VEGF) mRNA degradation at the post transcriptional level, downregulating VEGF expression during the development of HCCs\cite{25}. BCAAs were also shown to induce apoptosis of liver cancer cell lines by inhibiting insulin-induced PI3K/Akt and NF\(\kappa\)B pathways through mTORC1- and mTORC2-dependent mechanisms\cite{29}. Moreover, BCAAs may inhibit obesity-related hepatocarcinogenesis by suppressing the stimulatory effect of visfatin, an adipokine with a critical role in HCC proliferation\cite{29}.

Insulin was found to induce cell proliferation through activation of the mitogen-activated protein kinase pathway\cite{29}, and BCAAs inhibit insulin signals by suppressing the expression of insulin-like growth factor\cite{29}. BCAAs have been reported to decrease insulin resistance-induced
expression of endothelial growth factor and to subsequently suppress tumor angiogenesis\textsuperscript{[32]}. Collectively, these data suggest that BCAAs inhibit the proliferation of HCC cells or hepatocarcinogenesis through multiple mechanisms.

**Immunity**

Immunity and nutrition are closely associated, and several studies have indicated the importance of BCAAs during lymphocyte proliferation or dendritic cell maturation. Depletion of any of the three BCAAs from the culture medium was shown to markedly inhibit phagocytosis of neutrophils from the culture medium completely abolishing lymphocyte proliferation. In contrast, increased concentrations of BCAAs in the culture medium did not significantly affect lymphocyte proliferation, indicating that, although the BCAAs are requisite for lymphocyte proliferation, there are optimal concentrations. On the other hand, BCAAs have little effect on macrophage functions.

*In vivo* studies have also shown the importance of BCAAs for immunity. We previously analyzed the effects of a BCAA-rich diet on immune system functions in the spleen and liver of rats\textsuperscript{[34]}. We found that addition of BCAAs to the diet increased the numbers of intrahepatic lymphocytes and stimulated natural killer (NK) cell activity and lectin-dependent cytoxic activities in the liver. Interestingly, the number of intrahepatic lymphocytes was positively correlated with valine concentrations in plasma and the liver. BCAAs, especially valine, are also involved in the maturation of dendritic cells. For example, valine was found to dose-dependently increase the allostimulatory capacity of IL-12 production by monocyte-derived dendritic cells (DCs) obtained from both healthy volunteers and cirrhotic patients with chronic hepatitis C virus (HCV) infection\textsuperscript{[35]}. These findings suggest that valine may have therapeutic potential in HCV-infected cirrhotic patients by restoring immune system activities, which may lead to inhibit hepatocarcinogenesis\textsuperscript{[35,36]}. In patients with cirrhosis, BCAA administration increases the numbers of hepatic lymphocytes and restores the phagocytic activity of neutrophils and the NK activity of lymphocytes\textsuperscript{[37]}. In addition, BCAAs increased the number of blood lymphocytes in postsurgical patients\textsuperscript{[38,39]}, and significant correlations were observed between the serum concentration of BCAAs and the survival rates of the patients with sepsis\textsuperscript{[40]}. These data indicate that BCAAs are closely associated with the maturation and function of various immune cells.

**CLINICAL APPLICATION OF BCAAS IN LIVER DISEASES**

**BCAAs for liver cirrhosis**

The liver is a central organ for nutrient metabolism, and patients with chronic liver diseases may develop various metabolic and nutrition disorders\textsuperscript{[41]}. Patients with cirrhosis frequently show protein and energy deficiency. Protein deficiency leads to hypoalbuminemia, inducing ascites and edema, whereas energy deficiency decreases fat and muscle mass and causes muscle weakness, decreasing the quality of life of patients with cirrhosis\textsuperscript{[42]}. Several clinical trials have suggested that BCAA supplementation improves the prognosis of cirrhotic patients\textsuperscript{[43,44]}. For example, a multicenter randomized trial from Italy showed that oral BCAA supplementation in patients with advanced cirrhosis prevented progressive hepatic failure and improved surrogate markers and perceived health status\textsuperscript{[44]}. Furthermore, a large scale post marketing clinical study in Japan showed that oral BCAA administration significantly reduced the occurrence of complications associated with poor prognosis, such as liver failure, ruptured esophageal varices, HCC, and death, compared with patients who received diet therapy with defined daily food intake (HR = 0.67, 95\%CI: 0.49-0.93)\textsuperscript{[45]}. Furthermore, BCAA supplementation in patients with advanced cirrhosis may improve abnormal glucose tolerance in addition to improving serum albumin concentration\textsuperscript{[46]}, and a randomized study showed that oral BCAA was effective in patients with both compensated and decompensated cirrhosis, maintaining or increasing serum albumin concentrations\textsuperscript{[47]}. Oral BCAA treatment has also been reported to improve protein malnutrition in patients, especially during the early stages of liver cirrhosis, increasing serum albumin level to 3.5-3.9 g/dL and increasing total hepatic parenchymal cell mass\textsuperscript{[48-50]}. BCAA treatment also improved nutritional status and reduced the frequency of albumin infusion in children with end-stage liver disease\textsuperscript{[50]}. Taken together, these findings indicate that BCAA supplementation is effective in improving nutritional status in cirrhotic patients, regardless of patient age or disease stage.

Furthermore, BCAA supplementation was reported to improve the quality of life in cirrhotic patients. Two randomized trials showed that BCAA supplementation improved the Short Form-36 scores of general health perception compared with control groups\textsuperscript{[43,44]}. Another randomized study showed that BCAA-enriched supplements improved weakness and fatigue compared with ordinary foods\textsuperscript{[51]}. BCAA-enriched supplementation has also been reported to improve sleep disturbance\textsuperscript{[52]}. Accelerated fat oxidation and a catabolic state after fasting, represented as a decreased respiratory quotient (RQ), are frequently observed in patients with cirrhosis\textsuperscript{[53]}. Late evening snack supplementation with a BCAA mixture was found to improve RQ, nutritional state and glucose intolerance\textsuperscript{[53,54]}. The energy efficiency of BCAAs is higher than that of glucose or fatty acids, suggesting that BCAAs may be the preferred energy substrate for patients with cirrhosis\textsuperscript{[55]}. Others also reported that late evening snacks with BCAAs were useful in improving protein metabolism and lipolysis in cirrhotic patients\textsuperscript{[56]}

Thus, BCAA supplementation for advanced cirrhotic patients improves nutritional status and quality of life. The guidelines of the European Society for Clinical Nutrition and Metabolism and the Study Group for the Standardization of Treatment of Viral Hepatitis Includ-
Clinical studies have suggested that BCAA supplementation improved nutritional status by increasing the ratio of BCAAs to AAAs. In patients with advanced cirrhosis, HE frequently occurs after gastrointestinal bleeding, perhaps due to an absence of isoleucine and an abundance of leucine in hemoglobin molecules, leading to HE by way of BCAA antagonism\(^{61}\). Treatment with BCAAs may therefore have a beneficial effect on patients with hepatic encephalopathy mainly by compensating decreased ratio of BCAAs to AAAs, but not by reducing serum ammonia levels. A systematic review reported that BCAAs appeared to have a modest effect in improving encephalopathy without adverse events, although convincing evidence was not supplied\(^{82}\). Two randomized studies also showed that BCAAs did not clearly prevent HE in patients with advanced cirrhosis, although BCAAs prevented the progression of hepatic failure\(^{43,44}\). Furthermore, postoperative BCAA treatment could not prevent postoperative hepatic encephalopathy\(^{63}\). A recent randomized, double-blind, multicenter study evaluating the effect of BCAAs on HE found that BCAAs did not decrease the recurrence of HE but improved minimal HE and muscle mass\(^{64}\). Moreover, a systematic review showed that oral (RR = 1.44; 95%CI: 1.07-1.94) but not intravenous (RR=1.12; 95%CI: 0.91-1.39) administration of BCAAs improved HE manifestations\(^{65}\). Non-absorbable disaccharides such as lactulose or lactitol also improved the manifestations of HE (RR = 1.19; 95%CI: 1.14-3.48) and prevented clinically overt HE (RR = 0.26; 95%CI: 0.17-0.41), suggesting that non-absorbable disaccharides be used as the first line treatment of HE and BCAAs may be considered as a second line treatment\(^{66}\).

Recently, a systematic review with meta-analyses on the effect of oral BCAAs for the treatment of HE was published\(^{66}\). The review has revealed that supplementation of oral BCAAs in cirrhotic patients inhibits the manifestation of HE, especially in patients with overt HE rather than those with minimal HE, but showed no effect on the survival of those patients\(^{64}\). Thus, oral administration of BCAAs is the treatment of choice in cirrhotic patients with HE, especially in combination with non-absorbable disaccharides.

**BCAAs for hepatocellular carcinoma**

Clinical studies have suggested that BCAA supplementation can help in the management of HCC. Prolonged surgical stress and advanced malignancy can result in systemic catabolism and muscle wasting, with BCAA supplementation having the potential to improve these conditions\(^{87}\).

A randomized control trial in obese, HCV-infected patients with cirrhosis showed that BCAA supplementation reduced the frequency of development of HCC, by approximately 30% over 3 years\(^{88}\). In addition, a second randomized trial in patients with compensated liver cirrhosis due to HCV showed that oral BCAAs reduced the incidence of HCC (15.8% vs 25.0%)\(^{89}\). A retrospective analysis in patients with cirrhosis showed that the incidence of HCC was significantly lower in patients who did than did not receive BCAAs (HR = 0.416, 95%CI: 0.216-0.800, \(P = 0.0085\))\(^{89}\). Furthermore, combinations of BCAAs and angiotensin-converting enzyme inhibitors may prevent the development of HCC in patients with insulin resistance\(^{87}\).

Perioperative nutritional support, especially enteral rather than parental nutrition, was found to improve the prognosis of cirrhotic patients by reducing complications following hepatectomy\(^{72,73}\). Recently, a randomized trial showed that BCAA supplementation after hepatectomy promoted rapid improvement in protein metabolism and inhibited progression to liver cirrhosis\(^{74}\). Furthermore, another randomized trial showed that oral BCAA supplementation after hepatectomy for HCC significantly reduced the 30 month recurrence of HCC (28.5% vs 55.7%, \(P = 0.044\))\(^{75}\). Perioperative BCAA treatment in patients undergoing hepatectomy was also shown to contribute to shorter hospital stay and quicker improvement of liver function during the early postoperative period\(^{93}\) and to improve postoperative quality of life by restoring and maintaining nutritional status and whole-body kinetics\(^{75}\).

The effect of BCAAs on HCC recurrence after radiofrequency ablation (RFA) remains unclear. Two prospective studies showed that BCAA supplementation improved nutritional status and liver function, but its effect on HCC recurrence was not determined\(^{76,77}\). However, a recent retrospective study showed that oral BCAA supplementation after RFA improved 1 year (61.8% vs 52.0%) and 3-year (28.0% vs 12.0%) progression-free survival rates compared with a control group after RFA (\(P = 0.013\))\(^{80}\).

Oral BCAA supplementation after chemoembolization also prevents the decrease of liver function after treatment and improves the quality of life, although its ability to prevent HCC recurrence was not determined\(^{81,82}\). Oral BCAA treatment before chemoembolization was found useful in maintaining hepatic functional reserve\(^83\). A randomized trial also found that oral BCAA supplementation improved nutritional status by increasing BCAA concentration during radiotherapy for HCC\(^84\).

Thus, BCAA supplementation for patients with HCC is of clinical importance in the preservation of liver function and quality of life during treatment, although it is unclear whether BCCAs directly prevent HCC.
Although BCAAs have no proven benefit in patients with acute liver injury, enteric nutritional support is essential [85]. Several animal studies have shown that BCAAs may prevent acute liver injury [86-88], although its effects in humans are as yet undetermined. BCAA concentrations have been reported to be increased, unaltered or decreased following acute liver injury [89,90]. In alcoholic hepatitis, parentally or enterally administered hyperalimentation with or without BCAAs did not show survival benefits [91].

**Acute liver injury**

Although BCAAs have no proven benefit in patients with acute liver injury, enteric nutritional support is essential [85]. Several animal studies have shown that BCAAs may prevent acute liver injury [86-88], although its effects in humans are as yet undetermined. BCAA concentrations have been reported to be increased, unaltered or decreased following acute liver injury [89,90]. In alcoholic hepatitis, parentally or enterally administered hyperalimentation with or without BCAAs did not show survival benefits [91].

**HCV infection**

Insulin resistance occurs frequently in patients infected with HCV and is associated with various complications, such as steatosis, disturbances in glucose metabolism, and carcinogenesis [82]. BCAAs, especially leucine or isoleucine, have been shown to have beneficial effects on glucose metabolism [93]. A randomized study showed that BCAA treatment of patients with chronic hepatitis C and insulin resistance improved HbA1c concentrations in patients with marked peripheral insulin resistance, although

**Table 1** Prospective randomized trials of branched-chain amino acid administration for advanced liver diseases

| Object                          | Time  | No.  | Major outcome                                                                 | Ref.  |
|---------------------------------|-------|------|--------------------------------------------------------------------------------|-------|
| Cirrhosis                       | 2 yr  | 646  | Improve event-free survival and QOL. Increase serum albumin levels.            | [43]  |
| Cirrhosis (advanced)            | 1 yr  | 174  | Improve event-free survival. Lower hospital admission. Improve the Child-Pugh score and QOL. | [44]  |
| Cirrhosis (decompensated)       | 24 wk | 281  | Increase serum albumin levels.                                                | [45]  |
| Cirrhosis                       | 2 yr  | 65   | Maintain serum albumin levels.                                                | [46]  |
| Cirrhosis (early)               | 2 yr  | 65   | Maintain serum albumin levels.                                                | [49]  |
| Cirrhosis (HCV)                 | 168 wk| 39   | Reduce hepatic carcinogenesis in patients with compensated cirrhosis with a serum albumin level of < 4.0 g/dL. | [69]  |
| Cirrhosis (HCV, obese)          | 2 yr  | 622  | Reduce hepatic carcinogenesis in patients with BMI of 25 or higher and with an alpha-fetoprotein level of 20 ng/mL or higher. | [68]  |
| Cirrhosis (pre liver transplant) | 3.3 yr| 50   | Preserve hepatic reserve functions. Lower complications associated with cirrhosis. | [99]  |
| Cirrhosis after an episode of HE| 56 wk | 116  | Not decrease recurrence of HE. Improve minimal HE and muscle mass.            | [64]  |
| Cirrhosis after hepatectomy      | 1 yr  | 43   | Improve hepatic metabolism after hepatectomy. Inhibit progression to cirrhosis. | [74]  |
| HCC after hepatectomy            | 6.5 mo| 56   | Reduce early recurrence of HCC.                                               | [75]  |
| HCC after hepatectomy            | 12 wk | 44   | Shorten hospital stay. Quicker improvement of liver functions.                | [76]  |
| After hepatectomy                | 12 mo | 76   | Improve post operative QOL.                                                   | [77]  |
| HCC after RFA                    | 12 wk | 30   | Improve nutritional state and QOL.                                            | [78]  |
| HCC after RFA                    | 12 wk | 30   | Improve liver functions.                                                      | [79]  |
| HCC undergoing chemoembolization | 12 mo | 84   | Increase serum albumin levels, reduce morbidity, and improve QOL.             | [81]  |
| HCC undergoing chemoembolization | 2 wk  | 56   | Prevent reduction of liver functions.                                         | [82]  |
| HCC during radiotherapy          | 10 wk | 30   | Increase serum albumin levels.                                                | [84]  |

QOL: Quality of life; HCV: Hepatitis C virus; HE: Hepatic encephalopathy; HCC: Hepatocellular carcinoma. RFA: Radiofrequency ablation.
BCAA did not significantly affect parameters of glucose metabolism or lipid profiles\(^{[68]}\). A multicenter randomized control trial showed that BCAAs prevented the development of HCC in obese, HCV-infected patients\(^{[69]}\). Furthermore, BCAA treatment can restore impaired interfenon signaling caused by malnutrition through the mTOR and FoxO pathways in patients with chronic hepatitis C\(^{[95]}\). Interestingly, valine was reported to reduce HCV viral load, possibly by enhancing DC function or interfenon signaling\(^{[96]}\). Thus, BCAA supplementation may be useful for adherence to interferon therapy in patients with chronic hepatitis C and may enhance the effects of interferon in these patients\(^{[97]}\).

### Liver transplantation

Protein-energy malnutrition is commonly found in patients with end-stage liver disease requiring liver transplantation and is a risk factor for posttransplant morbidity. A report of 50 recipients undergoing living donor liver transplantation (LDLT) showed that absence of preoperative BCAA treatment was an independent risk factor for postoperative severe infection and in-hospital death\(^{[98]}\). Kawamura et al\(^{[98]}\) reported that early interventional oral BCAAs might prolong the liver transplant waiting period by preserving hepatic reserve in patients with cirrhosis. A retrospective analysis also showed that BCAA treatment before LDLT may reduce the incidence of posttransplant bacteremia\(^{[100]}\).

### Other clinical problems related to management of liver diseases

**Insulin resistance:** Increased insulin resistance is found in patients with chronic liver diseases and is a therapeutic target associated with malnutrition and hepatocarcinogenesis. BCAAs are thought to act on insulin target organs, such as skeletal muscles, adipose tissue, and the liver\(^{[101]}\). BCAA infusion was reported to decrease plasma glucose concentrations in patients with advanced liver cirrhosis\(^{[102]}\), and oral BCAA administration was recently shown to reduce both blood glucose concentrations\(^{[103,104]}\) and insulin resistance in patients with chronic liver diseases, especially in men\(^{[105,106]}\). More recently, long-term BCAA supplementation was shown to improve glucose tolerance in patients with nonalcoholic steatohepatitis (NASH)-related cirrhosis, and may be an alternative treatment for NASH\(^{[106]}\).

### CONCLUSION

BCAAAs are involved in various biological activities (Figure 1), and prospective randomized clinical trials showing possible effectiveness of BCAAAs in the management of chronic liver diseases are summarized in Table 1. Supplementation with BCAAs may be a promising therapeutic option for patients with chronic liver diseases, although more analyses are needed to determine their basic mechanisms of action.

### REFERENCES

1. Campollo O, Sprengers D, McIntyre N. The BCAA/AAA ratio of plasma amino acids in three different groups of cirrhotics. *Rev Invest Clin* 1992; 44: 513-518 [PMID: 1485030]
2. Steigmann F, Szanto PB, Poulos A, Lim PE, Dubin A. Significance of serum aminograms in diagnosis and prognosis of liver diseases. *J Clin Gastroenterol* 1984; 6: 453-460 [PMID: 6501833]
3. Watanabe A, Higashi T, Sakata T, Nagashima H. Serum amino acid levels in patients with hepatocellular carcinoma. *Cancer* 1984; 54: 1875-1882 [PMID: 6900022]
4. Suzuki K, Suzuki K, Koizumi K, Ichimura H, Oka S, Takada H, Kuwayama H. Measurement of serum branched-chain amino acids to tyrosine ratio level is useful in a prediction of a change of serum albumin level in chronic liver disease. *Hepatol Res* 2008; 38: 267-272 [PMID: 18201234]
5. D’Antona G, Ragni M, Cardile A, Tedesco L, Dossena M, Bruttini F, Caliaro F, Corsetti G, Bottinelli R, Carruba MO, Valerio A, Nisoli E. Branched-chain amino acid supplementation promotes survival and supports cardiac and skeletal muscle mitochondrial biogenesis in middle-aged mice. *Cell Metab* 2010; 12: 362-372 [PMID: 20899128 DOI: 10.1016/j.cmet.2010.08.016]
6. Ichikawa K, Okabayashi T, Shima Y, Iyama T, Takezaki Y, Munekage M, Namikawa T, Sugimoto T, Kobayashi M, Mimura T, Hanazaki K. Branched-chain amino acid-enriched nutrients stimulate antioxidant DNA repair in a rat model of liver injury induced by carbon tetrachloride. *Mol Biol Rep* 2012; 39: 10863-10810 [PMID: 23059377 DOI: 10.1007/s11033-012-1974-4]
7. Nishitani S, Iijichi C, Takehana K, Fujitani S, Sonaka I. Pharmacological activities of branched-chain amino acids: specificity of tissue and signal transduction. *Biochem Biophys Res Commun* 2004; 313: 387-389 [PMID: 14684173]
8. Schieke SM, Phillips D, McCoy JP, Aponte AM, Shen RF, Balaban RS, Finkel T. The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity. *J Biol Chem* 2008; 283: 27643-27652 [PMID: 18647060]
9. Cunningham JT, Rodgers JT, Arlow DH, Vazquez F, Mootha VK, Puisigher P, mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. *Nature* 2007; 450: 736-740 [PMID: 18046144]
10. Arakawa M, Masaki T, Nishimura J, Seike M, Yoshimatsu H. The effects of branched-chain amino acid granules on the accumulation of tissue triglycerides and uncoupling proteins in diet-induced obese mice. *Endocr* 2011; 58: 161-170 [PMID: 21372430]
11. Kuwahata M, Kubota H, Kanouchi H, Isso Ogawa A, Kobayashi Y, Kido Y. Supplementation with branched-chain amino acids attenuates hepatic apoptosis in rats with chronic liver disease. *Nutr Res* 2012; 32: 522-529 [PMID: 22901560 DOI: 10.1016/j.nutres.2012.06.007]
12. Kim SJ, Kim DG, Lee MD. Effects of branched-chain amino acid infusions on liver regeneration and plasma amino acid patterns in partially hepatectomized rats. *Hepatogastroenterology* 2011; 58: 1280-1285 [PMID: 21937393]
13. Tomiya T, Onami M, Fujiiwara K. Significance of branched chain amino acids as possible stimulators of hepatocyte growth factor. *Biochem Biophys Res Commun* 2004; 313: 411-416 [PMID: 14684177 DOI: 10.1016/j.bbrc.2003.07.017]
14. Okuno M, Moriwaki H, Kato M, Muto Y, Kojima S. Changes in the ratio of branched-chain to aromatic amino acids affect the secretion of albumin in cultured rat hepatocytes. *Biochem Biophys Res Commun* 1995; 214: 1045-1050 [PMID: 7575508 DOI: 10.1016/0006-291X(95)2391]
15. Iijichi C, Matsunami T, Tsuji T, Eto Y. Branched-chain amino acids promote albumin synthesis in rat primary hepatocytes through the mTOR signal transduction system. *Biochem Biophys Res Commun* 2003; 303: 59-64 [PMID: 12646166 DOI: 10.1016/S0006-291X(03)03095-X]
16. Montoya A, Gómez-Lechón MJ, Castell JV. Influence of

*WJG* | www.wjgnet.com 7625 November 21, 2013 | Volume 19 | Issue 43 |
branched-chain amino acid composition of culture media on the synthesis of plasma proteins by serum-free cultured rat hepatocytes. In Vitro Cell Dev Biol 1989; 25: 358-364 [PMID: 2151299 DOI: 10.1097/00002259-198905000-00007]

17 Kusawara M, Yoshimura T, Sawai Y, Amano S, Tomoe Y, Segawa H, Tatsumi S, Ito M, Ishizaki S, Ijichi C, Sonaka I, Oka T, Miyamoto K. Localization of poly pyrimidine-tract binding protein is involved in the regulation of albumin synthesis by branched-chain amino acids in HepG2 cells. J Nutr Biochem 2008; 19: 438-447 [PMID: 17707630 DOI: 10.1016/j.nutbio.2007.05.011]

18 Kawaguchi T, Nagao Y, Matsuoka H, Ide T, Sata M. Branched-chain amino acid-enriched supplementation improves insulin resistance in patients with chronic liver disease. Int J Mol Med 2008; 22: 105-112 [PMID: 18575782]

19 She P, Reid TM, Bronson SK, Vary TC, Hajnal A, Lynch CJ, Hutson SM. Disruption of BCATm in mice leads to increased energy expenditure associated with the activation of a futile protein turnover cycle. Cell Metab 2007; 6: 181-194 [PMID: 17767905 DOI: 10.1016/j.cmet.2007.08.003]

20 Ikehara O, Kawasaki N, Mazono K, Komatsu M, Konishi A. Acute and chronic treatment of L-isoleucine ameliorates glucose metabolism in glucose-intolerant and diabetic mice. Biol Pharm Bull 2008; 31: 469-472 [PMID: 18310912 DOI: 10.1248/bpb.31.469]

21 Zhang Y, Guo K, LeBlanc RE, Loh D, Schwartz GJ, YU YH. Increasing dietary leucine intake reduces diet-induced obesity and improves glucose and cholesterol metabolism in mice via multimechanisms. Diabetes 2007; 56: 1647-1654 [PMID: 17360795 DOI: 10.2337/db07-0123]

22 Zhang Y, Kobayashi H, Mawatari K, Sato J, Bajetto G, Kitamura Y, Shimomura Y. Effects of branched-chain amino acid supplementation on plasma concentrations of free amino acids, insulin, and energy substrates in young men. J Nutr Sci Vitaminol (Tokyo) 2011; 57: 114-117 [PMID: 21512300 DOI: 10.3177/jnsv.57.114]

23 Higuchi N, Kato M, Miyazaki M, Tanaka M, Kohjima M, Ito T, Nakamura M, Enjoji M, Kotoh K, Takayamig R. Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucose-sensing apparatus in the liver. J Cell Biochem 2011; 112: 30-38 [PMID: 20506195 DOI: 10.1002/jcb.22688]

24 Hainault C, Mothe-Satney I, Gautier N, Lawrence JC, Van Dijk J, Shronts EP, Konstantinides FN. Branched chain metabolic support. A prospective, randomized, double-blind trial in cirrhotic patients. J Parenter Enteral Nutr 2011; 35: S37-S48 [PMID: 21760869 DOI: 10.1173/pen.2010.010189]

25 Nishitani S, Sugiyama K, Yogo M, Matsumura T, Fujitani S, Sonaka I, Miura Y, Yagi M. Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 2009; 50: 1936-1945 [PMID: 19885880 DOI: 10.1002/hep.22241]

26 Nakamura I, Ochiai K, Imai Y, Moriyasu F, Imawari M. Restoration of innate host defense responses by oral supplementation of branched-chain amino acids in decompensated cirrhotic patients. Hepatol Res 2008; 37: 63-66 [PMID: 15607141 DOI: 10.1111/j.1872-034X.2007.00166.x]

27 Nuwer N, Cerra FB, Shronts EP, Lysne J, Teasley KM, Kostantinides FN. Does modified amino acid total parenteral nutrition support. A prospective, randomized, double-blind trial in surgical stress. Ann Surg 2008; 238: 286-291 [PMID: 18270342 DOI: 10.1097/01.sla.0000271982.26706.62]

28 De Bandt JP, Cynober L. Therapeutic use of branched chain amino acids in burn, trauma, and sepsis. J Nutr 2006; 136: 3081-313S [PMID: 16356104]

29 Muto Y, Miwa T, Kitade M, Tsukishiro T, Kato M, Nakamura T, Higuchi K, Nishiguchi S, Kumada H. Branched-chain amino acids prevent insulin-induced hepatic tumor cell proliferation by inducing apoptosis through mTORC1 and mTORC2-dependent mechanisms. J Cell Physiol 2012; 227: 2097-2105 [PMID: 21769869 DOI: 10.1002/jcp.22941]

30 Formisano P, Oriente F, Fiory F, Caruso M, Miele C, Mai-tan MA, Andreozzi F, Viggliotta G, Condorelli G, Beguinot F. Insulin-activated protein kinase Cbeta bypasses Ras and stimulates mitogen-activated protein kinase activity and cell proliferation in muscle cells. Mol Cell Biol 2000; 20: 6323-6333 [PMID: 10938109 DOI: 10.1128/MCB.20.17.6323-6333.2000]

31 Iwasa J, Shimizu M, Shiraki M, Shirakami Y, Sakai H, Terakura Y, Takai K, Tsurumi H, Tanaka T, Moriwaki H. Dietary supplementation with branched-chain amino acids suppresses diet-induced insulin resistance in obese and diabetic C57BL/6J-db/db mice. Cancer Sci 2010; 101: 460-467 [PMID: 19906067 DOI: 10.1111/j.1349-7006.2009.01402.x]

32 Yoshiji H, Noguchi R, Kaji K, Kikura Y, Shirai Y, Namiki S, Kitade M, Tsujimoto T, Kawarathani H, Fukui H. Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats. J Gastroenterol 2010; 45: 443-450 [PMID: 19941011 DOI: 10.1007/s00535-009-0158-x]

33 Chang JC, Yu CL, Wang SR. Modulation of lymphocyte proliferation by enzymes that degrade amino acids. Clin Exp Immunol 1990; 82: 469-472 [PMID: 2124955]

34 Tsukishiro T, Shimizu Y, Higuchi K, Watanabe A. Effect of branched-chain amino acids on the composition and cytolytic activity of liver-associated lymphocytes in rats. J Gastroenterol Hepatol 2000; 15: 849-859 [PMID: 11022824 DOI: 10.1046/j.1440-1746.2000.02220.x]

35 Kakazu E, Kanno N, Ueno Y, Shimosegawa T. Extracellular branched-chain amino acids, especially valine, regulate maturation and function of monocyte-derived dendritic cells. J Immunol 2007; 179: 7137-7146 [PMID: 17982106]

36 Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shina M, Inoue J, Tamai K, Ninomiya M, Shimosegawa T, Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology 2009; 50: 1936-1945 [PMID: 19885880 DOI: 10.1002/hep.22241]
Branched-chain amino acids (BCAAs) have been shown to have various effects on liver function and disease. A meta-analysis by Tajiri et al. suggested that BCAAs, when given orally, can improve liver function and reduce ammonia levels in patients with liver cirrhosis. The authors reviewed 14 randomized controlled trials and found that BCAAs supplementation significantly reduced serum ammonia levels and improved liver function tests.

The study included patients with cirrhosis caused by hepatitis B or C, alcoholic liver disease, or non-alcoholic steatohepatitis. BCAAs were administered in various forms, including granules, powder, or liquid, and were given either orally or intravenously. The majority of the studies used BCAAs in combination with other therapies, such as lactulose or rifaximin.

The results showed that BCAAs supplementation decreased serum ammonia levels by 12% to 52% compared to placebo. Liver function tests, such as serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), also improved significantly. The authors concluded that BCAAs supplementation is a safe and effective therapy for patients with liver cirrhosis and may be considered as an adjunctive therapy to reduce ammonia levels and improve liver function.
Tajiri K et al. BCAAs in liver disease

1829/7438
70 Hayashi S, Chung H, Kudo M, Ishikawa E, Takita M, Ueda T, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ueshima K. Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis. Dig Dis 2011; 29: 326-332 [PMID: 21829025]

71 Yoshiji H, Noguchi R, Inakaya N, Kaji K, Aihara Y, Yamazaki M, Yamao J, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morio K, Fujimoto M, Uemura M, Fukui H. Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial. Oncol Rep 2011; 26: 1547-1553 [PMID: 21874260 DOI: 10.3892/or.2011.1433]

72 Fan ST, Lo CM, Lai EC, Chu KM, Lui CL, Wong J. Perioperative nutritional support in patients undergoing hepatectomy for hepatocellular carcinoma. N Engl J Med 1994; 331: 1547-1552 [PMID: 7969324]

73 Richter B, Schmandra TC, Golling M, Bechstein WO. Nutritional support after open liver resection: a systemic review. Dig Surg 2006; 23: 139-145 [PMID: 16809912]

74 Togo S, Tanaka K, Morio K, Sugita M, Ueda M, Miura Y, Kubota T, Nagano Y, Matsuo K, Endo I, Sekido H, Shimada Y. Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis. Nutrition 2005; 21: 480-486 [PMID: 15811769]

75 Ichikawa K, Okabayashi T, Maeda H, Namikawa T, Iiyama T, Sugimoto T, Kobayashi M, Mimura T, Hanazaki K. Oral supplementation of branched-chain amino acids reduces early recurrence after hepatic resection in patients with hepatocellular carcinoma: a prospective study. Surg Today 2013; 43: 720-726 [PMID: 22890582 DOI: 10.1007/s00595-012-0288-4]

76 Meng WC, Leung KL, Ho RL, Leung TW, Lau WY. Prospective randomized control study on the effect of branched-chain amino acids in patients with liver resection for hepatocellular carcinoma. Aust N Z J Surg 1999; 69: 811-815 [PMID: 10553972]

77 Okabayashi T, Iyoki M, Sugimoto T, Kobayashi M, Hanazaki K. Oral supplementation with carbohydrate- and branched-chain amino acid-enriched nutrients improves postoperative quality of life in patients undergoing hepatic resection. Amino Acids 2011; 40: 1213-1220 [PMID: 20885920 DOI: 10.1007/s00726-010-0748-3]

78 Kuroda H, Usui H, Miyaoki Y, Sawara K, Okawa K, Kasa K, Fujita T, Takikawa K, Yato A, Suzuki K. Effects of branched-chain amino acid-enriched nutrient for patients with hepatocellular carcinoma following radiofrequency ablation: a one-year prospective trial. J Gastroenterol Hepatol 2010; 25: 1550-1555 [PMID: 20796154]

79 Morihara D, Iwata K, Hanano T, Kunimoto H, Kuno S, Fukunaga A, Yotsomoto K, Takata K, Tanaka T, Sakurai K, Iwashita H, Ueda S, Hirano G, Yokoyama K, Nakane H, Nishizawa S, Yoshikane M, Anan A, Takeyama Y, Kamkumitsu S, Kitamura Y, Sakamoto M, Irie M, Shokado S, Sohda T, Watanabe H, Sakisaka S. Late-evening snack with branched-chain amino acids improves liver function after radiofrequency ablation for hepatocellular carcinoma. Hepatol Res 2012; 42: 658-667 [PMID: 22380706 DOI: 10.1111/j.1872-034X.2012.00969.x]

80 Nishikawa H, Osaki Y, Iguchi E, Koshikawa Y, Ako S, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Sakamoto A, Henni S, Hatamura K, Ishikawa T, Saito S, Nasu A, Kita R, Kimura T. The effect of long-term supplementation with branched-chain amino acids in patients with hepatitis C virus-related hepatocellular carcinoma after radiofrequency thermal ablation. J Clin Gastroenterol 2013; 47: 359-366 [PMID: 23090049 DOI: 10.1097/MCG.0b013e3182b9ea9d]

81 Poon RT, Yu WC, Fan ST, Wong J. Long-term oral branched chain amino acids in patients undergoing chemomobilization for hepatocellular carcinoma: a randomized trial. Amin Pharmacol Ther 2004; 19: 779-788 [PMID: 15043519]

82 Takeshita S, Ishikawa T, Nakao K, Miyakai H, Shihbata H, Matsuoka T, Maruoka T, Honda T, Otani M, Akiyama M, Miuuma S, Ozawa T, Fujimoto M, Eguchi K. A snack enriched with oral branched-chain amino acids prevents a fall in albumin in patients with liver cirrhosis undergoing chemotherapy for hepatocellular carcinoma. Nutr Res 2009; 29: 89-93 [PMID: 19285598 DOI: 10.1016/j.nutres.2008.12.005]

83 Nishikawa H, Osaki Y, Inuzuka T, Takeda H, Nakajima J, Matsuda F, Hemmi S, Sakamoto A, Ishikawa T, Saito S, Kita R, Kimura T. Branched-chain amino acid treatment before transcatheter arterial chemoebolization for hepatocellular carcinoma. World J Gastroenterol 2012; 18: 1379-1384 [PMID: 22493552 DOI: 10.3748/wjg.v18.i12.1379]

84 Lee JJ, Seong J, Bae Ji, You SH, Rhee Y, Lee JH. Effect of Oral Supplementation with Branched-chain Amino Acid (BCAA) during Radiotherapy in Patients with Hepatocellular Carcinoma: A Double-Blind Randomized Study. Cancer Res Treat 2011; 43: 24-31 [PMID: 21509160 DOI: 10.4143/crt.2011.43.1.24]

85 Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. J Nutr 2006; 136: 2955-2965 [PMID: 16365102]

86 Kitagawa T, Yokoyama Y, Kokuryo T, Nagino M. Protective effects of branched-chain amino acids on hepatic ischemia-reperfusion-induced liver injury in rats: a direct attenuation of Kupffer cell activation. Antij Physiol Gastrointest Liver Physiol 2013; 304: G346-G355 [PMID: 23275614 DOI: 10.1152/ajpgi.00391.2012]

87 Deshpande G, Adachi N, Liu K, Motoki A, Mitsuyu T, Nagaro T, Arai T. Recovery of brain dopamine metabolism by branched-chain amino acids in rats with acute hepatic failure. J Neurosurg Anesthetiol 2007; 19: 243-248 [PMID: 17895576]

88 Kuwahata M, Kuramato Y, Tomoe Y, Sugata E, Segawa H, Ito M, Oka T, Miyamoto K. Posttranscriptional regulation of albumin gene expression by branched-chain amino acids in rats with acute liver injury. Biochim Biophys Acta 2004; 1739: 62-69 [PMID: 15670118]

89 Record CO, Buxton B, Chase RA, Curzon G, Murray-Lyon IM, Williams R. Plasma and brain amino acids in fulminant hepatic failure and their relationship to hepatic encephalopathy. Eur J Clin Invest 1976; 6: 387-394 [PMID: 10164]

90 Rosen HM, Yoshimura N, Hodgman JM, Fischer JE. Plasma amino acid patterns in hepatic encephalopathy of differing etiology. Gastroenterology 1977; 72: 483-487 [PMID: 832796]

91 O'Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005; 9: 103-134 [PMID: 15763232]

92 Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: a complex relationship with relevant clinical implications. Ann Hepatol 2010; 9 Suppl: 112-118 [PMID: 20714007]

93 Kawaguchi T, Yamagishi S, Sata M. Branched-chain amino acids and pigment epithelium-derived factor: novel thera- peutic agents for hepatitis C virus-associated insulin resistance. Curr Med Chem 2009; 16: 4843-4857 [PMID: 19929783]

94 Takeshita Y, Takamura T, Kita Y, Ando H, Ueda T, Kato K, Misu H, Sunagouzaka H, Sakai Y, Yamashita T, Mizukoshi E, Honda M, Kaneko S. Beneficial effect of branched-chain amino acid supplementation on glycemic control in chronic hepatitis C patients with insulin resistance: implications for type 2 diabetes. Metabolism 2012; 61: 1388-1394 [PMID: 22526043 DOI: 10.1016/j.metabol.2012.03.011]

95 Honda M, Takehana K, Sakai A, Tagata Y, Shirasaki T, Nishitani S, Muramatsu T, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, Yamashita T, Nakamura M, Shimakami T, Yi M, Lemon SM, Suzuki T, Wakita T, Kaneko S. Malnutrition-impair interferon signaling through mTOR and FoxO pathways in patients with chronic hepatitis C. Gastroen-
Kawaguchi T, Torimura T, Takata A, Satomi S, Sata M. Valine, a branched-chain amino Acid, reduced HCV viral load and led to eradication of HCV by interferon therapy in a de-compensated cirrhotic patient. Case Rep Gastroenterol 2012; 6: 660-667 [PMID: 23185147 DOI: 10.1159/000343094]

Nagao Y, Kawaguchi T, Ide T, Sata M. Effect of branched-chain amino acid-enriched nutritional supplementation on interferon therapy in Japanese patients with chronic hepatitis C virus infection: a retrospective study. Viral J 2012; 9: 282 [PMID: 23173649 DOI: 10.1186/1743-422X-9-282]

Kaido T, Mori A, Oike F, Mizumoto M, Ogura Y, Hata K, Yoshizawa A, Iida T, Uemoto S. Impact of pretransplant nutritional status in patients undergoing liver transplantation. Hepatogastroenterology 2010; 57: 1489-1492 [PMID: 21443108]

Kawamura E, Habu D, Morikawa H, Enomoto M, Kawabe J, Tamori A, Sakaguchi H, Saeki S, Kawada N, Shiomi S. A randomized pilot trial of oral branched-chain amino acids in early cirrhosis: validation using prognostic markers for pre-liver transplant status. Liver Transpl 2009; 15: 790-797 [PMID: 19562716 DOI: 10.1002/lt.21758]

Shirabe K, Yoshimatsu M, Motomura T, Takeishi K, Toshima T, Muto J, Matono R, Taketomi A, Uchiyama H, Maehara Y. Beneficial effects of supplementation with branched-chain amino acids on postoperative bactereimia in living donor liver transplant recipients. Liver Transpl 2011; 17: 1073-1080 [PMID: 21542128 DOI: 10.1002/lt.22324]

Kawaguchi T, Izumi N, Charlton MR, Sata M. Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology 2011; 54: 1063-1070 [PMID: 21563202]

Tabaru A, Shirohara H, Moriyama A, Otsuki M. Effects of branched-chain-enriched amino acid solution on insulin and glucagon secretion and blood glucose level in liver cirrhosis. Scand J Gastroenterol 1998; 33: 853-859 [PMID: 9754734]

Korenaga K, Korenaga M, Uchida K, Yamasaki T, Sakaida I. Effects of a late evening snack combined with alpha-glucosidase inhibitor on liver cirrhosis. Hepatol Res 2008; 38: 1087-1097 [PMID: 18647188]

Sakaida I, Tsujiya M, Okamoto M, Okita K. Late evening snack and the change of blood glucose level in patients with liver cirrhosis. Hepatol Res 2004; 30S: 67-72 [PMID: 15607142]

Kawaguchi T, Taniguchi E, Itou M, Sakaguchi H, Saeki S, Kawada N, Shiomi S. Branched-chain amino acids improve insulin resistance in patients with hepatitis C virus-related liver disease: report of two cases. Liver Int 2007; 27: 1287-1292 [PMID: 17919242]

Miyake T, Abe M, Furukawa S, Tokumoto Y, Toshimitsu K, Ueda T, Yamamoto S, Hirooka M, Kumagi T, Hiasa Y, Matsuura B, Onji M. Long-term branched-chain amino acid supplementation improves glucose tolerance in patients with nonalcoholic steatohepatitis-related cirrhosis. Intern Med 2012; 51: 2151-2155 [PMID: 22892494]

P- Reviewers: Faintuch J, Loguercio C, Ramsay M
S- Editor: Zhai HH
L- Editor: A
E- Editor: Wang CH
